The duration of Phase III trials can vary significantly, typically ranging from several months to several years. The length of the trial depends on various factors, including the type of cancer being studied, the expected time needed to observe a difference in outcomes, and the time required to enroll a sufficient number of participants. Long-term follow-up is often necessary to assess the treatment's impact on survival rates and quality of life.
